We are seeking strategic partners to develop a helminth diagnostic or anthelmintic resistance genotyping platform together. We can offer design, development and manufacturing services for field-based diagnostic platforms. We are specialized in nucleic-acid-based diagnostic techniques such as PCR and LAMP. We have successfully developed and launched a point-of-care rapid COVID-19 test and several animal disease diagnostic tests. We have an ISO13485 certificate for quality-assured manufacturing of in vitro diagnostic devices and consumables. We also have a strong R&D team specializing in infectious diseases, genetic bioinformatics, biomaterials, and biomedical engineering. Our affordable diagnostic solution also comes with the following advantages: freeze-dried reagents for room-temperature storage, delivery of results within 30 minutes, comparable performance to real-time PCR, and elimination of the DNA extraction step.

Oxford MEStar Ltd. was a spun-out company from the Institute of Biomedical Engineering of Oxford University in 2013. Oxford MEStar has collaborated with established companies to manufacture and distribute important assets, such as the
Oxsed RaViD COVID-19 test that international airports adopted. The capability to manufacture and supply high-volume COVID-19 tests during a period when the pandemic heavily impacted the supply chain demonstrates their deep network and expertise in rapid commercialization and robust pipelines. The company holds an ISO13285 certificate and a strong regulatory background. It has a high-standard QC system to ensure that the quality of its products satisfies MHRA, EMA, FDA, and NMPA (China) regulations and requirements.